Research article Special Issues

Incorporating mass vaccination into compartment models for infectious diseases

  • Received: 26 April 2022 Revised: 08 June 2022 Accepted: 14 June 2022 Published: 29 June 2022
  • The standard way of incorporating mass vaccination into a compartment model for an infectious disease is as a spontaneous transition process that applies to the entire susceptible class. The large degree of COVID-19 vaccine refusal, hesitancy, and ineligibility, and initial limitations of supply and distribution require reconsideration of this standard treatment. In this paper, we address these issues for models on endemic and epidemic time scales. On an endemic time scale, we partition the susceptible class into prevaccinated and unprotected subclasses and show that vaccine refusal/hesitancy/ineligibility has a significant impact on endemic behavior, particularly for diseases where immunity is short-lived. On an epidemic time scale, we develop a supply-limited Holling type 3 vaccination model and show that it is an excellent fit to vaccination data. We then extend the Holling model to a COVID-19 scenario in which the population is divided into two risk classes, with the high-risk class being prioritized for vaccination. In both cases, with and without risk stratification, we see significant differences in epidemiological outcomes between the Holling vaccination model and naive models. Finally, we use the new model to explore implications for public health policies in future pandemics.

    Citation: Glenn Ledder. Incorporating mass vaccination into compartment models for infectious diseases[J]. Mathematical Biosciences and Engineering, 2022, 19(9): 9457-9480. doi: 10.3934/mbe.2022440

    Related Papers:

  • The standard way of incorporating mass vaccination into a compartment model for an infectious disease is as a spontaneous transition process that applies to the entire susceptible class. The large degree of COVID-19 vaccine refusal, hesitancy, and ineligibility, and initial limitations of supply and distribution require reconsideration of this standard treatment. In this paper, we address these issues for models on endemic and epidemic time scales. On an endemic time scale, we partition the susceptible class into prevaccinated and unprotected subclasses and show that vaccine refusal/hesitancy/ineligibility has a significant impact on endemic behavior, particularly for diseases where immunity is short-lived. On an epidemic time scale, we develop a supply-limited Holling type 3 vaccination model and show that it is an excellent fit to vaccination data. We then extend the Holling model to a COVID-19 scenario in which the population is divided into two risk classes, with the high-risk class being prioritized for vaccination. In both cases, with and without risk stratification, we see significant differences in epidemiological outcomes between the Holling vaccination model and naive models. Finally, we use the new model to explore implications for public health policies in future pandemics.



    加载中


    [1] K. Liu, Y. Lou, Optimizing COVID-19 vaccination programs during vaccine shortages, Infect. Dis. Model. 7 (2022), 286–298. https://doi.org/10.1016/j.idm.2022.02.002 doi: 10.1016/j.idm.2022.02.002
    [2] F. Brauer, C. Castillo-Chavez, Z. Feng, Mathematical Models in Epidemiology, Springer-Verlag, New York, 2019.
    [3] L.-M. Cai, Z. Li, X. Song, Global analysis of an epidemic model with vaccination, J. Appl. Math. Comp., 57 (2018), 605–628. https://doi.org/10.1007/s12190-017-1124-1 doi: 10.1007/s12190-017-1124-1
    [4] M. Martcheva, An Introduction to Mathematical Epidemiology, Springer-Verlag, New York, 2015.
    [5] N. E. MacDonald, SAGE Working Group on Vaccine Hesitancy, Vaccine hesitancy: Definition, scope and determinants, Vaccine, 33 (2015), 4161–4164. https://doi.org/10.1016/j.vaccine.2015.04.036 doi: 10.1016/j.vaccine.2015.04.036
    [6] J. Arino, S. Portet, A simple model for COVID-19, Infect. Dis. Model., 5 (2020), 309–315. https://doi.org/10.1016/j.idm.2020.04.002 doi: 10.1016/j.idm.2020.04.002
    [7] G. Ledder, Mathematical Modeling for Epidemiology and Ecology, 2nd edition, Springer-Verlag, New York, in press.
    [8] S. Greenhalgh, C. Rozins, A generalized differential equation compartmental model of infectious disease transmission, Infect. Dis. Model., 6 (2021), 1073–1091. https://doi.org/10.1016/j.idm.2021.08.007 doi: 10.1016/j.idm.2021.08.007
    [9] H. W. Hethcote, The mathematics of infectious diseases, SIAM Rev., 42 (2000), 599—653.
    [10] S. Gazit, R. Shlezinger, G. Perez, R. Lotan, A. Peretz, A. Ben-Tov, et al., SARS-CoV-2 naturally acquired immunity vs. vaccine-induced immunity, reinfections versus breakthrough infections: A retrospective cohort study, Clin. Infect. Dis., (2022). https://doi.org/10.1093/cid/ciac262 doi: 10.1093/cid/ciac262
    [11] P. van den Driessche, J. Watmough, Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission, Math. Biosci., 180 (2002), 29–48. https://doi.org/10.1016/S0025-5564(02)00108-6 doi: 10.1016/S0025-5564(02)00108-6
    [12] A. R. McLean, S. M. Blower, Imperfect vaccines and herd immunity to HIV, Proc. R. Soc. Lond. B, 253 (1993), 9–13. https://doi.org/10.1098/rspb.1993.0075 doi: 10.1098/rspb.1993.0075
    [13] S. M. Moghadas, T. N. Viches, K. Zhang, C. R. Wells, A. Shoukat, B. H. Singer, et al., The impact of vaccination on coronavirus disease 2019 (COVID-19) outbreaks in the United States, Clin. Infec. Dis., 73 (2020), 2257–2264. https://doi.org/10.1093/cid/ciab079 doi: 10.1093/cid/ciab079
    [14] The Centers for Disease Control and Prevention, COVID-19 Vaccinations in the United States, 2022. Available from https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-total-admin-rate-total
    [15] Our World in Data, State-by-state Data on COVID-19 Vaccinations in the United States, 2022. Available from https://ourworldindata.org/us-states-vaccinations
    [16] G. Ledder, M. Homp, Using a COVID-19 model in various classroom settings to assess effects of interventions, PRIMUS, 32 (2021), 278–297. https://doi.org/10.1080/10511970.2020.1861143 doi: 10.1080/10511970.2020.1861143
    [17] E. H. Elbasha, A. B. Gumel, Vaccination and herd immunity thresholds in heterogeneous populations, J. Math. Biol., (2021). https://doi.org/10.1007/s00285-021-01686-z doi: 10.1007/s00285-021-01686-z
    [18] The Centers for Disease Control and Prevention, New Admissions of Patients with Confirmed COVID-19, United States, 2022. Available from https://covid.cdc.gov/covid-data-tracker/#new-hospital-admissions
    [19] The Centers for Disease Control and Prevention, COVID-19 Pandemic Planning Scenarios, 2020. Available from https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html#five-scenarios.
    [20] The COVID Tracking Project, Our Data, 2020. Available from https://covidtracking.com/data
    [21] A. W. Byrne, D. McEvoy, A. B. Collins, K. Hunt, M. Casey, A. Barber, et al., Inferred duration of infectious period of SARS-CoV-2: Rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases, BMJ Open, 10 (2020). https://doi.org/10.1136/bmjopen-2020-039856 doi: 10.1136/bmjopen-2020-039856
    [22] X. He, E. H. Y. Lau, P. Wu, X. Deng, J. Wang, X. Hao, et al., Temporal dynamics in viral shedding and transmissibility of COVID-19, Nat. Med., 26 (2020), 672–675. https://doi.org/10.1038/s41591-020-0869-5 doi: 10.1038/s41591-020-0869-5
    [23] Y. Liu, L.-M. Yan, L. Wan, T.-X. Xiang, A. Le, J.-M. Liu, et al., Viral dynamics in mild and severe cases of COVID-19, Lancet Infect. Dis., 20 (2020), 656–657. https://doi.org/10.1016/S1473-3099(20)30232-2 doi: 10.1016/S1473-3099(20)30232-2
    [24] S. A. Lauer, K. H. Grantz, Q. Bi, F. K. Jones, Q. Zheng, H. R. Meredith, et al., The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: Estimation and application, Ann. Int. Med., (2020). https://doi.org/10.7326/M20-0504 doi: 10.7326/M20-0504
    [25] J. A. Lewnard, V. X. Liu, M. L. Jackson, M. A. Schmidt, B. L. Jewell, J. P. Flores, et al., Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: prospective cohort study, BMJ, 369 (2020). https://doi.org/10.1136/bmj.m1923 doi: 10.1136/bmj.m1923
    [26] C. Faes, S. Abrams, D. Van Beckhoven, G. Meyfroidt, E. Vlieghe, N. Hens, Time between symptom onset, hospitalisation and recovery or death: statistical analysis of Belgian COVID-19 patients, Int. J. Environ. Res. Public Health, (2020). https://doi.org/10.3390/ijerph17207560 doi: 10.3390/ijerph17207560
    [27] Cough and Cold Preparations Global Market Report 2021: COVID-19 Implications and Growth to 2030, The Business Research Company, 2021.
    [28] R. Ke, E. Romero-Severson, S. Sanche, N. Hengartner, Estimating the reproductive number $ {\cal{R}}_0$ of SARS-CoV-2 in the United States and eight European countries and implications for vaccination, J. Theo. Biol., 517 (2021). https://doi.org/10.1016/j.jtbi.2021.110621 doi: 10.1016/j.jtbi.2021.110621
    [29] Our World in Data, Coronavirus Vaccinations, 2022. Available from https://ourworldindata.org/covid-vaccinations
    [30] G. Ledder, Mathematics for the Life Sciences: Calculus, Modeling, Probability, and Dynamical Systems, Springer-Verlag, New York, 2013.
  • Reader Comments
  • © 2022 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(1584) PDF downloads(122) Cited by(1)

Article outline

Figures and Tables

Figures(11)  /  Tables(1)

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog